IOVA - Iovance Biotherapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
26.14
+0.97 (+3.85%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close25.17
Open25.09
Bid25.24 x 3000
Ask26.53 x 1800
Day's Range25.02 - 26.59
52 Week Range7.26 - 26.59
Volume1197327
Avg. Volume1,318,874
Market Cap3.3B
Beta (5Y Monthly)2.03
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Hedge Funds Have Never Been This Bullish On Iovance Biotherapeutics, Inc. (IOVA)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Iovance Biotherapeutics, Inc. (IOVA)

    Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]

  • We Think Iovance Biotherapeutics (NASDAQ:IOVA) Can Afford To Drive Business Growth
    Simply Wall St.

    We Think Iovance Biotherapeutics (NASDAQ:IOVA) Can Afford To Drive Business Growth

    We can readily understand why investors are attracted to unprofitable companies. By way of example, Iovance...

  • ETF Trends

    The Unloved Biotechnology ETF Rally

    Biotechnology stocks have been outperforming over the past month, but ETF investors seem disinterested and are even trimming exposure to this sector. In a weekly update on the flow of money in and out of stock funds, PiperJaffray analyst Christopher J. Raymond pointed out that investors pulled a net $99 million out of healthcare and biotech-related funds in the one-week period ended on Wednesday, Barron's reports. The latest redemptions seems surprising given the recent outperformance of the biotechnology sector.

  • Hedge Funds Are Dumping Iovance Biotherapeutics, Inc. (IOVA)
    Insider Monkey

    Hedge Funds Are Dumping Iovance Biotherapeutics, Inc. (IOVA)

    Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]

  • Benzinga

    Stifel Bullish On Iovance And Fate Therapeutics, Neutral On Bluebird Bio

    Stifel initiated coverage on a trio of oncology-focused biotechs Tuesday, recommending buying two and staying sidelined on a third. The Analyst Benjamin Burnett initiated coverage of: bluebird bio Inc ...

  • Have Insiders Been Buying Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares This Year?
    Simply Wall St.

    Have Insiders Been Buying Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares This Year?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

  • Iovance Biotherapeutics: Technical Analysis and Strategy
    TheStreet.com

    Iovance Biotherapeutics: Technical Analysis and Strategy

    Iovance Biotherapeutics is worth speculating on, as the company's cancer treatments are promising, Jim Cramer said during his Mad Money program Friday night. IOVA intends to commercialize "autologous cell therapy products for solid tumors and blood cancers." Their approach uses a patient's own immune cells to attack cancer cells -- cutting edge stuff, if you ask me. In the daily bar chart of IOVA, below, we can see that prices made a seven-plus month base around $10 before a gap to the upside got the rally going.

  • Iovance Biotherapeutics: Buy the Dip?
    Motley Fool

    Iovance Biotherapeutics: Buy the Dip?

    The company is flush with cash and wields a promising therapeutic pipeline. Is its recent tumble a buying opportunity?

  • IOVA Stock Could See Another Massive Rebound
    Schaeffer's Investment Research

    IOVA Stock Could See Another Massive Rebound

    A bullish signal just flashed for IOVA that could have it trading back near its five-year highs

  • Iovance Biotherapeutics, Inc. (IOVA) Q2 2019 Earnings Call Transcript
    Motley Fool

    Iovance Biotherapeutics, Inc. (IOVA) Q2 2019 Earnings Call Transcript

    IOVA earnings call for the period ending June 30, 2019.

  • Biotech Merger Activity Has Been Hot In 2019 — So, What's One More?
    Investor's Business Daily

    Biotech Merger Activity Has Been Hot In 2019 — So, What's One More?

    Iovance Biotherapeutics hit a "clear inflection point" in the second quarter, analysts said Friday — but that didn't stop the biotech stock from plunging on wider-than-expected losses.

  • 3 Top Biotech Stocks to Buy Right Now
    Motley Fool

    3 Top Biotech Stocks to Buy Right Now

    These three biotech stocks might be outstanding buys right now.

  • Does Market Volatility Impact Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) Share Price?
    Simply Wall St.

    Does Market Volatility Impact Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) Share Price?

    If you own shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) then it's worth thinking about how it contributes to...

  • Here's Why Iovance Biotherapeutics Soared 50% in June
    Motley Fool

    Here's Why Iovance Biotherapeutics Soared 50% in June

    The clinical-stage biopharma announced promising data at a major conference.

  • 3 Stocks With a Perfect Smart Score
    TipRanks

    3 Stocks With a Perfect Smart Score

    The S&P 500 recently closed out an all-time high of 2,954, while the Dow is also within touching distance of record territory. That’s excellent news for existing shareholders, but it does make finding new investing ideas a challenge. However, a deep analysis of stocks – covering everything from analyst activity to headline sentiment and even momentum – can turn up a few stock picks that are still primed to outperform. The Smart Score pulls together eight data sets – including the factors mentioned above – to create a rating that unites eight different equity insights.Here are three “Perfect 10” stocks to buy now, according to the Smart Score system. All three stocks boast the highest possible score of “10,” indicating that these stocks represent compelling investing opportunities right now. Let’s see why these stocks earn such high scores… Iovance (IOVA)Iovance Biotherapeutics is a clinical-stage biotech focused on developing immunotherapies to treat cancer. Specifically, the company is working on personalized tumor infiltrating lymphocytes known as TILs. What’s exciting is that Iovance's proprietary TILs are the first cell therapy to show significant efficacy in solid tumors. Right now the company is conducting phase II clinical trials assessing the efficacy and safety of TILs for patients with metastatic melanoma, head and neck cancer, as well as cervical cancer. Shares have more than doubled year-to-date, and as we can see below the stock scores a ‘perfect’ Smart Score of 10. Most notably, 9 analysts have published buy ratings on the stock in the last three months. So no hold or sell ratings here. Analysts reiterated their bullish calls after IOVA presented two posters at the annual meeting of the American Society of Clinical Oncology (ASCO), showing encouraging efficacy of TILs in melanoma and cervival cancer. “Iovance’s TIL products, LN-144 and LN-145, are continuing to deliver significant clinical promise in these two indications, and we believe investors are starting to recognize and reward it” wrote Chardan Capital’s Geulah Livshits following the event. Her buy rating comes with a $30 price target (41% upside potential). But that’s not the only datapoint in IOVA’s favor. The stock also boasts bullish blogger opinions, increased hedge fund activity and a very positive sentiment from investors. Five-star blogger Bhavneesh Sharma rates IOVA a buy. He explains that Iovance is being rumored as an attractive takeover candidate after breakthrough results of its TILs technology in advanced refractory cervical cancer. Netflix (NFLX)Streaming giant Netflix looks like a compelling investing proposition right now, according to its Smart Score. Indeed, top-rated Goldman Sachs analyst Heath Terry has placed Netflix on the firm’s elite Conviction List of top stock ideas. He wasn’t deterred by the company’s light second-quarter guidance, writing: “As Netflix’s content investments, distribution partnerships and marketing spend drive subscriber growth significantly above consensus expectations and the company approaches an inflection point in cash profitability, we believe shares of NFLX will continue to significantly outperform,” he said.“We remain Buy rated and raise our 12-month price target to $460 from $450 to reflect faster subscriber growth expectations, particularly in international markets.” From current levels that indicates upside potential of 24%.Terry is one of 24 analysts who have recently published NFLX buy ratings. That’s versus just 3 hold ratings and 1 sell rating. Encouragingly, Piper Jaffray’s Michael Olson has also just carried out a deep dive into Netflix’s second quarter. He revealed that his study of search trends suggests year-over-year 11.7% growth in US subscribers and 45.8% international growth. That easily beats Netflix’s guidance of 8.2%. for US subscribers, and international growth of 36.5%.Meanwhile, the company also enjoys Very Bullish news sentiment, blogger opinions, increased hedge fund activity and positive return on equity. News sentiment is buzzing as Netflix has just revealed that its new comedy caper “Murder Mystery” enjoyed the biggest opening weekend ever for a Netflix Film. According to the firm’s tweet, “30,869,863 accounts watched ‘Murder Mystery’ in its first 3 days.” Paycom Software (PAYC)Based in Oklahoma, Paycom is an online payroll and human resource technology provider. It is attributed with being one of the first fully online payroll providers and has offices throughout the US. Shares have exploded 84% year-to-date, thanks to strong earnings results and a guidance raise. The company reported revenue growth of 30% and adjusted EBITDA of $103 million. According to five-star KeyBanc analyst Brent Bracelin further growth lies ahead. He has just boosted his price target from $215 to $246. “Further analysis of the HR competitive landscape suggests the growth and improving margin profile at HR SaaS leader PAYC appears sustainable, particularly given roughly 70% of HR applications are still tied to on-premise deployments implying a long and stable growth runway” comments Bracelin. He raises estimates citing increased confidence in the company maintaining industry leading growth rate while improving margins.In addition, investors show Very Positive sentiment on PAYC, as do hedge funds and bloggers. Hedge fund gurus with promininent positions in the stock include both Ken Fisher and Joel Greenblatt of Gotham Asset Management. Discover more Top Smart Score stocks here

  • 3 Top Healthcare Stocks to Buy Right Now
    Motley Fool

    3 Top Healthcare Stocks to Buy Right Now

    These three healthcare stocks could be outstanding additions to your portfolio.

  • Cancer Therapy Stocks Soar After Pfizer Deal
    Investopedia

    Cancer Therapy Stocks Soar After Pfizer Deal

    Cancer therapy stocks rallied after Pfizer made a deal to boost its oncology offerings. These industry players may also be takeover targets.

  • Why Iovance Biotherapeutics Stock Jumped Today
    Motley Fool

    Why Iovance Biotherapeutics Stock Jumped Today

    Pfizer's acquisition of Array appeared to cause investors to wonder whether a big deal could be in store for Iovance.

  • Did Hedge Funds Drop The Ball On Iovance Biotherapeutics, Inc. (IOVA) ?
    Insider Monkey

    Did Hedge Funds Drop The Ball On Iovance Biotherapeutics, Inc. (IOVA) ?

    Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before the Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the first […]

  • Zacks Small Cap Research

    PHIO: Two Compounds Entering Clinic in 2020

    Since the beginning of the year, the company has announced a new collaborations with Glycostem Therapeutics, the promotion of Dr. Gerrit Dispersyn to CEO and the appointment of Dr. John Barrett as CDO. Phio’s lead candidate, RXI-762, is pursuing immuno-oncology indications in collaboration with Center for Cancer Immune Therapy (CCIT) and Iovance Biotherapeutics. Development efforts are centered on reducing the immune checkpoints that appear on the surface of tumor infiltrating lymphocytes (TILs) in an approach that can be layered on to current manufacturing processes.

  • Cancer-Fighting Stocks & ETF: What You Need to Know
    Zacks

    Cancer-Fighting Stocks & ETF: What You Need to Know

    Many biotech stocks soared after they presented very promising cancer treatment results at the ASCO conference

  • Iovance and Amgen Are Making Cancer History
    Bloomberg

    Iovance and Amgen Are Making Cancer History

    Iovance shares have climbed more than 50 percent since its data was first released in mid-May, including a 10 percent surge on Monday (the company presented at the Chicago conference on Friday). Amgen shares climbed more than 4 percent this week, while Mirati Therapeteutics Inc. – a smaller rival that’s working on a similar lung cancer drug to Amgen’s surged more than 45 percent in that same time. It’s easy to over-hype initial results, and there have been many instances where thrilling early data and a ballooning stock price deteriorated over time. In the case of Iovance and Amgen, though, the excitement is warranted, and the impact should extend beyond a few amped-up investors.